# Single Source for the Continuation of the Data Management and Coordinating Center (DMCC) for Rare Diseases Clinical Research Network (RDCRN) (U2C Clinical Trial Not Allowed)

Source: https://welltoldgrants.com/grants/rfa-tr-24-021-single-source-for-the-continuation-of-the-data/  
Official notice: https://www.grants.gov/search-results-detail/353422

> National Institutes of Health offered grants to colleges and universities. Applications closed on July 22, 2024.

| Field | Value |
|---|---|
| Opportunity number | RFA-TR-24-021 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | July 22, 2024 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.350, 93.853 |

## Who can apply

- Public and State controlled institutions of higher education

Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

## What the grant funds

This is a non-competitive funding opportunity intended to fund a single award. NCATS is announcing its intent to issue a single source cooperative agreement to Cincinnati Childrens Hospital Medical Center (CCHMC) to support the Data Management and Coordinating Center. The Rare Diseases Clinical Research Network (RDCRN) is intended to advance and improve diagnosis, management, and treatment of numerous, diverse rare diseases through highly collaborative, multi-site, patient-centric, translational, and clinical research with an emphasis on early and timely identification of individuals with rare diseases and clinical trial readiness. The DMCC facilitates and supports the activities of each individual Rare Diseases Clinical Research Consortium (RDCRC) along with trans-network activities that broadly facilitate the advancement of rare disease research via four avenues: administrative support, data management support, clinical research support and patient engagement, and broad dissemination of information. The RDCRCs will continue conducting research conducted under a separate NOFO.

## Questions people ask

### Is RFA-TR-24-021 still open?

No. It closed on July 22, 2024.

### Who can apply for Single Source for the Continuation of the Data Management and Coordinating Center (DMCC) for Rare Diseases Clinical Research Network (RDCRN) (U2C Clinical Trial Not Allowed)?

National Institutes of Health accepted applications from colleges and universities. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Single Source for the Continuation of the Data Management and Coordinating Center (DMCC) for Rare Diseases Clinical Research Network (RDCRN) (U2C Clinical Trial Not Allowed)?

Closed July 22, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### Who has been funded under RFA-TR-24-021?

NIH RePORTER lists 1 project funded under RFA-TR-24-021 in fiscal 2025 to 2026, at 1 institution.

### Who has won National Center for Advancing Translational Sciences grants before?

The largest recipients over five fiscal years were University of Pittsburgh - of the Commonwealth System of Higher Education, Vanderbilt University Medical Center, Duke University. The program made 867 awards worth $3.1 billion in that time.